Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and platinum chemotherapy in lung adenocarcinoma with brain metastases
NCT06056115Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of tislelizumab in lung adenocarcinoma, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-Free Survival at 1 year. Started May 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06056115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056115.